FDA-approved1,2Evidence: Large human trialsLiver

Terlipressin1

Also called Terlivaz1,2

Key takeaway

Terlipressin is a lab-made analogue of the hormone vasopressin and the active ingredient in Terlivaz.1,2 FDA approved Terlivaz in 2022 to improve kidney function in adults with hepatorenal syndrome with a rapid loss of kidney function, a complication studied in people with cirrhosis.1,2 In the trial behind the approval, 29% of patients given terlipressin had their kidney failure reverse, compared with 16% given placebo. The label carries a boxed warning about serious or fatal respiratory failure.1

Terlipressin at a glance

What it isA synthetic vasopressin analogue that acts mainly on vasopressin V1 receptors and is also converted in the body to lysine-vasopressin, according to the label.1
FDA statusFDA-approved. Drugs@FDA lists Terlivaz with an original approval date of September 14, 2022. The label has a boxed warning about serious or fatal respiratory failure.1,2
Human evidenceOne randomized, double-blind, placebo-controlled trial (CONFIRM) in 300 adults with hepatorenal syndrome, described in the label.1
Evidence strengthLarge randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned

What is terlipressin?

Terlipressin is a synthetic analogue of vasopressin, a peptide hormone that acts on vasopressin V1 and V2 receptors.1

In the United States it is the active ingredient of Terlivaz, approved under NDA 022231, according to Drugs@FDA.2

How does terlipressin work?

The label states that terlipressin is about twice as selective for vasopressin V1 receptors as for V2 receptors, and that it acts both as a prodrug for lysine-vasopressin and on its own.1

It is thought to increase blood flow to the kidneys in hepatorenal syndrome by lowering pressure in the portal veins and raising effective blood volume and arterial pressure, according to the label.1

What do human studies show?

The label describes CONFIRM, a multicenter, double-blind, randomized, placebo-controlled trial in 300 adults with cirrhosis, fluid in the abdomen and rapidly worsening hepatorenal syndrome; 199 received terlipressin and 101 placebo, and both groups also received albumin.1

The main outcome was verified reversal of hepatorenal syndrome. It occurred in 58 of 199 patients (29.1%) given terlipressin and 16 of 101 (15.8%) given placebo, according to the label.1

What the evidence base contains

  • Large randomized human trial CONFIRM (NCT02770716): a randomized, double-blind, placebo-controlled trial in 300 adults with cirrhosis and hepatorenal syndrome, described in the label as the study that assessed its effectiveness.1

Evidence-strength label: Large randomized human trials. How this label is assigned

Is terlipressin FDA-approved?

Yes. Drugs@FDA lists Terlivaz, application NDA 022231, with an original approval date of September 14, 2022.2

The Terlivaz label cited here (DailyMed SPL version 8, published October 26, 2026) states that it is indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function, and that patients with very advanced kidney impairment are unlikely to benefit.1

The label carries a boxed warning that Terlivaz may cause serious or fatal respiratory failure, with higher risk in patients with volume overload or the most severe grade of acute-on-chronic liver failure.1

The label also states that it must not be used in patients with low blood oxygen or worsening breathing symptoms, or with ongoing reduced blood flow to the heart, limbs or intestines.1

Timeline

  1. FDA approves Terlivaz, according to Drugs@FDA.2
  2. DailyMed publishes the Terlivaz label version cited on this page.1

What is still unknown?

How it compares with other treatments for hepatorenal syndrome: the trial described in the label compared terlipressin with placebo, with albumin in both groups.1

Its benefit beyond the population studied: the label limits the indication to adults with hepatorenal syndrome and rapid loss of kidney function.1

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Terlipressin: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Terlipressin are a bounded selection, not every registration or paper about Terlipressin. For the years before Terlipressin was added, PeptideScanner took at most 30 ClinicalTrials.gov registrations that list Terlipressin as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 30 PubMed papers that name Terlipressin in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

FDA-approved as Terlivaz for hepatorenal syndrome. A randomized, placebo-controlled trial of 300 adults described in the label found more reversals of hepatorenal syndrome with terlipressin than with placebo. The label has a boxed warning about serious or fatal respiratory failure.↗↗

Status sources checked through November 15, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Terlipressin?

FDA-approved as Terlivaz for hepatorenal syndrome. A randomized, placebo-controlled trial of 300 adults described in the label found more reversals of hepatorenal syndrome with terlipressin than with placebo. The label has a boxed warning about serious or fatal respiratory failure.↗↗

The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
3
Source years
15
Drugs@FDA applications
1

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Collection changes

What did PeptideScanner add most recently?

  1. Literature metadata · added November 15, 2026

    A Noninferiority Trial Comparing 2 Days vs 5 Days of Terlipressin and Ceftriaxone in Terms of 5-Day Rebleeding for Patients With Acute Gastroesophageal Variceal Hemorrhage.↗Source date November 9, 2026
  2. Literature metadata · added November 15, 2026

    The use of terlipressin to treat refractory hypotension during allograft kidney transplantation: a report of 4 cases and literature review.↗Source date November 4, 2026
  3. Clinical trials · added November 15, 2026

    ClinicalTrials.gov record NCT06108362↗Source date October 13, 2026

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Terlipressin?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

63Selected dated records
65Connected citations
15Populated source years2006–2026
3/4Record lanes present

Registered human studies

Trial composition

29 of 30 selected trial records include at least one phase value; 30 of 30 include a status value in the retained structured contract.

PhasesPhase 3 11Phase 2 9Phase 4 6Not applicable 5Phase 1 1
Status at observationCompleted 26Active, not recruiting 2Not yet recruiting 1Recruiting 1

A phase value is unavailable here for 1 selected record; this is not counted as “no phase.”

PubMed bibliography

Publication composition

30 of 30 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 30Review 11Randomized Controlled Trial 8Systematic Review 8Meta-Analysis 6Comparative Study 5Research Support, Non-U.S. Gov't 5Multicenter Study 3Case Reports 1Clinical Trial 1Clinical Trial, Phase III 1Equivalence Trial 1Research Support, N.I.H., Extramural 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
1
FDA Federal Register documents
2
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
63

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 63 dated records

Research hub

Explore the Terlipressin evidence record

Open all 63 records →
63Dated records
3Evidence types
63Cited public sources
15Source years

Change ledger

Recently changed for Terlipressin

Open all 63 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT00089570

PeptideScanner retained ClinicalTrials.gov record NCT00089570 at 2026-11-15T21:47:40.408Z. Its registry update date was 2017-10-27, and PeptideScanner's reviewed identity mapping was terlipressin.

PeptideScanner change date
November 15, 2026
Cited source date
October 27, 2017
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00115947

PeptideScanner retained ClinicalTrials.gov record NCT00115947 at 2026-11-15T21:47:40.408Z. Its registry update date was 2006-03-09, and PeptideScanner's reviewed identity mapping was terlipressin.

PeptideScanner change date
November 15, 2026
Cited source date
March 9, 2006
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT00369694

PeptideScanner retained ClinicalTrials.gov record NCT00369694 at 2026-11-15T21:47:40.408Z. Its registry update date was 2008-09-25, and PeptideScanner's reviewed identity mapping was terlipressin.

PeptideScanner change date
November 15, 2026
Cited source date
September 25, 2008
Evidence lane
Clinical trials

Official-source collections

Source records for Terlipressin

Open the full research atlas →
PubMed30

30 with attributed title, venue, publication-date, and type metadata.

  1. Terlipressin in paediatric hepatorenal syndrome-acute kidney injury (HRS-AKI).Pediatric nephrology (Berlin, Germany) · 2026 02 19
  2. Terlipressin for Hepatorenal Syndrome in Patients With Early-Stage Acute-on-Chronic Liver Failure.Liver international : official journal of the International Association for the Study of the Liver · 2025 Dec
  3. The use of terlipressin to treat refractory hypotension during allograft kidney transplantation: a report of 4 cases and literature review.BMC anesthesiology · 2025 11 07
Explore all selected literature →
ClinicalTrials.gov30

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT06108362Registry update October 13, 2026 · completed at observation
  2. NCT07252401Registry update August 27, 2026 · current at observation
  3. NCT07719933Registry update July 28, 2026 · completed at observation
Explore all selected trial records →Explore all public record history →

Evidence types

Coverage by source year

Selected records span March 9, 2006 to November 9, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. National Library of Medicine1
  • U.S. Food and Drug Administration2
Dated updates connected to this profile · 63

Updates connected to this profile

Open the full cross-source timeline →
  1. Literature metadata

    A Noninferiority Trial Comparing 2 Days vs 5 Days of Terlipressin and Ceftriaxone in Terms of 5-Day Rebleeding for Patients With Acute Gastroesophageal Variceal Hemorrhage.↗

    PubMed lists PMID 38526204 in The American journal of gastroenterology as Journal Article, Randomized Controlled Trial, Equivalence Trial, Comparative Study, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-05-25 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  2. Literature metadata

    The use of terlipressin to treat refractory hypotension during allograft kidney transplantation: a report of 4 cases and literature review.↗

    PubMed lists PMID 41204083 in BMC anesthesiology as Journal Article, Case Reports, Review, with publication-date metadata of 2025-11-07 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT06108362↗

    PeptideScanner retained ClinicalTrials.gov record NCT06108362 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was terlipressin.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT07252401↗

    PeptideScanner retained ClinicalTrials.gov record NCT07252401 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-08-27, and PeptideScanner's reviewed identity mapping was terlipressin.↗

  5. Literature metadata

    From past to present to future: Terlipressin and hepatorenal syndrome-acute kidney injury.↗

    PubMed lists PMID 38353565 in Hepatology (Baltimore, Md.) as Journal Article, Review, Research Support, N.I.H., Extramural, with publication-date metadata of 2024-02-14 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  6. Literature metadata

    Terlipressin in paediatric hepatorenal syndrome-acute kidney injury (HRS-AKI).↗

    PubMed lists PMID 41711944 in Pediatric nephrology (Berlin, Germany) as Journal Article, Review, with publication-date metadata of 2026-02-19 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  7. Literature metadata

    [Research progress of terlipressin in the treatment of cirrhotic ascites-related complications].↗

    PubMed lists PMID 31941255 in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology as Journal Article, Review, with publication-date metadata of 2019-12-20 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  8. Literature metadata

    Terlipressin for Hepatorenal Syndrome in Patients With Early-Stage Acute-on-Chronic Liver Failure.↗

    PubMed lists PMID 41200852 in Liver international : official journal of the International Association for the Study of the Liver as Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-12 (month precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  9. Clinical trials

    ClinicalTrials.gov record NCT07719933↗

    PeptideScanner retained ClinicalTrials.gov record NCT07719933 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-07-28, and PeptideScanner's reviewed identity mapping was terlipressin.↗

  10. Clinical trials

    ClinicalTrials.gov record NCT06855758↗

    PeptideScanner retained ClinicalTrials.gov record NCT06855758 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-07-13, and PeptideScanner's reviewed identity mapping was terlipressin.↗

  11. Literature metadata

    Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome.↗

    PubMed lists PMID 33657294 in The New England journal of medicine as Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2021-03-04 (day precision). PeptideScanner associated the retained record with the identity slug terlipressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  12. Clinical trials

    ClinicalTrials.gov record NCT07304466↗

    PeptideScanner retained ClinicalTrials.gov record NCT07304466 at 2026-11-15T21:47:40.408Z. Its registry update date was 2026-04-29, and PeptideScanner's reviewed identity mapping was terlipressin.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    TERLIVAZ (terlipressin) for injection · SPL version 8 · published 2026-10-26 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  2. 2
    Drugs@FDA: TERLIVAZ (terlipressin acetate), NDA 022231 · original approval September 14, 2022 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026